Additional file 3 of Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Additional file 3: Supplementary Table 1. NCA PK parameter estimates for capmatinib and crizotinib in mouse plasma and brain. See Methods – Pharmacokinetics section for a description of abbreviations. Terminal phase parameters for crizotinib in brain could not be estimated and were not reported.